Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vyondys 53

Chemical Namegolodirsen
Dosage FormInjection (intravenous; 50 mg/mL)
Drug ClassOligonucleotides
SystemMusculoskeletal
CompanySarepta Therapeutics
Approval Year2019

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Last updated on 4/8/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyondys 53 (golodirsen) Prescribing Information.2019Sarepta Therapeutics, Inc. Cambridge, MA
Document TitleYearSource
Deflazacort, eteplirsen, and golodirsen for duchenne muscular dystrophy: effectiveness and value.2019ICER